Decreased CCL2 expression in MYCN-amplified cell lines may also favor ineffectiveness of immune checkpoint blockade therapy, and being able to modulate immune cell infiltration in neuroblastoma tumors could result in transformation of “cold” to “hot” tumors, rendering them more sensitive to immunotherapies (Fig. 6). This evidence concerns the gene CCL2 and neuroblastoma.